Cullin 3 as a novel target in diverse pathologies

Redox Biology

Volumn 1, Issue 1, 2013, Pages 366-372

  Andérica Romero, Ana Cristina ^a   González Herrera, Irma Gabriela ^b   Santamaría, Abel ^b   Pedraza Chaverri, José ^a  

^a Universidad Nacional Autonoma de Mexico Facultad de Quimica   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Cell cycle; Cullin 3; Nedd8; Nrf2; Oxidative stress; Proteasome

Indexed keywords

CULLIN; CULLIN 3; PROTEASOME; PROTEASOME INHIBITOR; SCAFFOLD PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ASTROCYTOMA; CARBOXY TERMINAL SEQUENCE; CELL CYCLE REGULATION; CELL FUNCTION; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASES; DNA REPLICATION; ENZYME ACTIVITY; ENZYME DEFECT; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HEMANGIOBLASTOMA; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM;

ANIMALS; CULLIN PROTEINS; DISEASE; HUMANS;

EID: 84880999260     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.07.003     Document Type: Review

References (81)

1. Jung T., Catalgol B., Grune T. The proteasomal system. Molecular Aspects of Medicine 2009, 30:191-296.
2. Hochstrasser M. Ubiquitin and intracellular protein degradation. Current Opinion in Cell Biology 1992, 4(6):1024-1031.
3. Peters J.M., Franke W.W., Kleinschmidt J.A. Distinct 19S and 20S subcomplexes of 26S proteasome and their distribution in the nucleus and the cytoplasm. The Journal of Biological Chemistry 1994, 269(10):7709-7718.
4. Thompson SJ, Loftus L.T., Ashley M.D., Meller R. Ubiquitin-proteasome system as a modulator of cell fate. Current Opinion in Pharmacology 2008, 8(1):90-95.
5. Rothwarf D.M., Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Science's Signal Transduction Knowledge Environment 1999, (5):RE1.
6. Lim M.S., Elenitoba-Johnson K.S. Ubiquitin ligases in malignant lymphoma. Leukemia and Lymphoma 2004, 45(7):1329-1339.
7. Miller J.R., Moon R.T. Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes and Development 1996, 10(20):2527-2539.
8. Lehman N.L. The ubiquitin proteasome system in neuropathology. Acta Neuropathologica 2009, 118:329-347.
9. Segref A., Hoppe T. Think locally: control of ubiquitin-dependent protein degradation in neurons. EMBO Reports 2009, 10(1):44-50.
10. Bedford L., Lowe J., Dick L.R., Mayer R.J., Brownell J.E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature Reviews 2011, 10:29-46.
11. Ulrich H.D. Natural substrates of the proteasome and their recognition by the ubiquitin system. Current Topics in Microbiology and Immunology 2002, 268:137-174.
12. Pintard L., Willems A., Peter M. Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. The EMBO Journal 2004, 23(8):1681-1687.
13. Furukawa M., Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Journal of Molecular Cell Biology 2005, 25(1):162-171.
14. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nature Reviews 2005, 6(1):9-20.
15. Sarikas A., Hartmann T., Pan Z.Q. The cullin protein family. Genome Biology 2011, 12(4):220.
16. Bosu D.R., Kipreos E.T. Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Division 2008, 3:7-11.
17. Marín I. Diversification of the cullin family. BMC Evolutionary Biology 2009, 9:267-278.
18. Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C., Conaway J.W., Nakayama K.I. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes and Development 2004, 18(24):3055-3065.
19. Wu J.T., Lin H.C., Hu Y.C., Chien C.T. Neddylation and deneddylation regulate Cul1 and Cul3 protein accumulation. Nature Cell Biology 2005, 7(10):1014-1020.
20. Boh B.K., Smith P.G., Hagen T. Neddylation-induced conformational control regulates cullin RING ligase activity in vivo. Journal of Molecular Biology 2010, 409(2):136-145.
21. Mori F., Nishie M., Piao Y.S., Kito K., Kamitani T., Takahashi H., Wakabayashi K. Acumulation of Nedd8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathology and Applied Neurobiology 2005, 31:53-61.
22. Parry G., Estelle M. Regulation of cullin-based ubiquitin ligases by the Nedd8/RUB ubiquitin-like proteins. Seminars in Cell and Developmental Biology 2004, 15:221-229.
23. Stogios P.J., Downs G.S., Jauhal J.J., Nandra S.K., Privé G.G. Sequence and structural analysis of BTB domain proteins. Genome Biology 2005, 6(10):R82.
24. Furukawa M., He Y.J., Borchers C., Xiong Y. Targeting of protein ubiquitination by BTB-cullin 3-Roc1 ubiquitin ligases. Nature cell biology 2003, 5:1001-1007.
25. Xu L., Wei Y., Reboul J., Vaglio P., Shin T.H., Vidal M., Elledge S.J., Harper J.W. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 2003, 425(6955):316-321.
26. Canning P., Cooper C.D., Krojer T., Murray J.W., Pike A.C., Chaikuad A, Keates T., Thangaratnarajah C., Hojzan V., Marsden B.D., Gileadi O., Knapp S., von Delft F., Bullock A.N. Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. The Journal of Biological Chemistry 2013, 288(11):7803-7814.
27. Luke-Glaser S., Pintard L., Lu C., Mains P.E., Peter M. The BTB protein MEL-26 promotes cytokinesis in C. elegans by a CUL-3 independent mechanism. Current Biology 2005, 15(18):1605-1615.
28. Pintard L., Willis J.H., Willems A., Johnson J.L., Srayko M., Kurz T., Glaser S., Mains P.E., Tyers M., Bowerman B., Peter M. The BTB protein MEL-26 is a substrate-specific adapter of the CUL-3 ubiquitin-ligase. Nature 2003, 425(6955):311-316.
29. Wang XJ, Sun Z, Villeneuve N.F., Zhang S., Zhao F, Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., Zhang D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29(6):1235-1243.
30. Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M. The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora-A. Biology Open 2012, 1(2):82-91.
31. Meraldi P., Honda R., Nigg E.A. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Current Opinion in Genetics and Development 2004, 14(1):29-36.
32. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nature Reviews Cancer 2006, 6(4):321-330.
33. Hayward D.G., Clarke R.B., Faragher A.J., Pillai M.R., Hagan I.M., Fry A.M. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Research 2004, 64(20):7370-7376.
34. Beck J., Maerki S., Posch M., Metzger T., Persaud A., Scheel H., Hofmann K., Rotin D., Pedrioli P., Swedlow J.R., Peter M., Sumara I. Ubiquitylation-dependent localization of PLK1 in mitosis. Nature Cell Biology 2013, 15(4):430-439.
35. Maerki S., Olma M.H., Staubli T., Steigemann P., Gerlich D.W., Quadroni M., Sumara I, Peter M. The Cul3-KLHL21 E3 ubiquitin ligase targets aurora B to midzone microtubules in anaphase and is required for cytokinesis. Journal of Cell Biology 2009, 187(6):791-800.
36. Singer J.D., Gurian-West M., Clurman B., Roberts J.M. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Development 1999, 13(18):2375-2387.
37. McEvoy J.D., Kossatz U., Malek N., Singer J.D. Constitutive turnover of cyclin E by Cul3 maintains quiescence. Molecular and Cellular Biology 2007, 27(10):3651-3666.
38. Todd M.C., Spruill S.C., Meerbrey K.L. Small interference RNA-mediated suppression of overexpressed cyclin E protein restores G1/S regulation in NIH-OVCAR-3 ovarian cancer cells. International Journal of Oncology 2009, 35(2):375-380.
39. Kossatz U., Breuhahn K., Wolf B., Hardtke-Wolenski M., Wilkens L., Steinemann D., Singer S., Brass F., Kubicka S., Schlegelberger B., Schirmacher P., Manns M.P., Singer J.D., Malek N.P. The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. The Journal of Clinical Investigation 2010, 120(11):3820-3833.
40. Schaefer H., Rongo C. KEL-8 is a substrate receptor for CUL3-dependent ubiquitin ligase that regulates synaptic glutamate receptor turnover. Molecular Biology of the Cell 2006, 17(3):1250-1260.
41. Wang W., Ding J., Allen E., Zhu P., Zhang L., Vogel H., Yang Y. Gigaxonin interacts with tubulin folding cofactor B and controls its degradation through the ubiquitin-proteasome pathway. Current Biology 2005, 15(22):2050-2055.
42. Dequen F., Bomont P., Gowing G., Cleveland D.W., Julien J.P. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1. Journal of Neurochemistry 2008, 107(1):253-264.
43. Shen H., Korutla L., Champtiaux N., Toda S., LaLumiere R., Vallone J., Klugmann M., Blendy J.A., Mackler S.A., Kalivas P.W. NAC1 regulates the recruitment of the proteasome complex into dendritic spines. Journal of Neuroscience 2007, 27(33):8903-8913.
44. Cullinan SB, Gordan JD, Jin J., Harper J.W., Diehl J.A. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Molecular and Cellular Biology 2004, 24(19):8477-8486.
45. Johnson J.L., Lu C., Raharjo E., McNally K., McNally F.J., Mains P.E. Levels of the ubiquitin ligase substrate adaptor MEL-26 are inversely correlated with MEI-1/katanin microtubule-severing activity during both meiosis and mitosis. Developmental Biology 2009, 330(2):349-357.
46. Friedman J.S., Ray J.W., Waseem N., Johnson K., Brooks M.J., Hugosson T., Breuer D., Branham K.E., Krauth D.S., Bowne S.J., Sullivan L.S., Ponjavic V., Gränse L., Khanna R., Trager E.H., Gieser L.M., Hughbanks-Wheaton D, Cojocaru R.I., Ghiasvand N.M., Chakarova CF, Abrahamson M., Göring H.H., Webster A.R., Birch D.G., Abecasis G.R., Fann Y., Bhattacharya S.S., Daiger S.P., Heckenlively J.R., Andréasson S., Swaroop A. Mutations in a BTB-Kelch protein, KLHL7, cause autosomal-dominant retinitis pigmentosa. American Journal of Human Genetics 2009, 84(6):792-800.
47. Königsberg-Fainstein M. Nrf2: La historia de un nuevo factor de transcripción que responde a estrés oxidativo. Revista de Educación Bioquímica 2007, 26(1):18-25.
48. Stewart D., Killeen E., Naquin R., Alam S., Alam J. Degradation of transcription factor Nrf2 via the UBIQuitin-proteasome pathway and stabilization by cadmium. The Journal of Biological Chemistry 2003, 278(4):2396-2402.
49. Kaspar J.W., Niture S.K., Jaiswal A.K. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radical Biology and Medicine 2009, 47:1304-1309.
50. Itoh K., Wakabayashi N, Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes and Development 1999, 13:76-86.
51. Lo S.C., Hannink M. CAND1-mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1. Molecular and Cellular Biology 2006, 26(4):1235-1244.
52. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends in Molecular Medicine 2004, 10(11):549-557.
53. Copple I.M., Goldring C.E., Kitteringham N.R., Park B.K. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 2008, 246:24-33.
54. Sekhar K.R., Rachakonda G., Freeman M.L. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicology and Applied Pharmacology 2010, 244:21-26.
55. Eggler A.L., Small E., Hannink M., Mesecar A.D. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. The Biochemical Journal 2009, 422:171-180.
56. Loignon M., Miao W., Hu L, Bier A., Bismar T.A., Scrivens P.J., Mann K., Basik M., Bouchard A., Fiset P.O., Batist Z., Batist G. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Molecular Cancer Therapeutics 2009, 8(8):2432-2440.
57. Okawa H., Motohashi H., Kobayashi A., Aburatani H., Kensler T.W., Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochemical and Biophysical Research Communications 2006, 339(1):79-88.
58. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S, Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Medicine 2006, 3(10):e420.
59. Padmanabhan B., Tong K.I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M., Kang M.I., Kobayashi A., Yokoyama S., Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular Cell 2006, 21(5):689-700.
60. Kaspar J.W., Jaiswal A.K. An autoregulatory loop between Nrf2 and Cul3-Rbx1 controls their cellular abundance. The Journal of Biological Chemistry 2010, 285(28):21349-21358.
61. Zhang Y., Yang J.W., Ren X., Yang J.M. NAC1 and HMGB1 enter a partnership for manipulating autophagy. Autophagy 2011, 7(12):1557-1568.
62. Nakayama K., Nakayama N., Davidson B., Sheu J.J., Jinawath N., Santillan A, Salani R., Bristow R.E., Morin P.J., Kurman R.J, Wang T.L., Shih IeM.A. BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(49):18739-18744.
63. Yeasmin S., Nakayama K., Ishibashi M., Katagiri A., Iida K., Purwana I.N., Nakayama N., Miyazaki K. Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clinical Cancer Research 2008, 14(6):1686-1691.
64. Ji L., Li H., Gao P., Shang G., Zhang D.D., Zhang N., Jiang T. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One 2013, 8(5):e63404.
65. Yamane Y., Furuichi M., Song R., Van N.T., Mulcahy R.T., Ishikawa T., Kuo M.T. Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. The Journal of Biological Chemistry 1998, 273:31075-31085.
66. Hayashi A., Suzuki H., Itoh K., Yamamoto M., Sugiyama Y. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochemical and Biophysical Research Communications 2003, 310:824-829.
67. Himmelbach A., Hoffmann T., Leube M., Höhener B., Grill E. Homeodomain protein ATHB6 is a target of the protein phosphatase ABI1 and regulates hormone responses in Arabidopsis. The EMBO Journal 2002, 21(12):3029-3038.
68. Boyden L.M., Choi M, Choate K.A., Nelson-Williams C.J., Farhi A., Toka H.R., Tikhonova I.R., Bjornson R., Mane S.M., Colussi G., Lebel M., Gordon R.D., Semmekrot B.A., Poujol A., Välimäki M.J., De Ferrari M.E., Sanjad S.A., Gutkin M., Karet F.E., Tucci J.R., Stockigt J.R., Keppler-Noreuil K.M., Porter C.C., Anand S.K., Whiteford M.L., Davis I.D., Dewar S.B., Bettinelli A., Fadrowski J.J., Belsha C.W., Hunley T.E., Nelson R.D., Trachtman H., Cole T.R., Pinsk M., Bockenhauer D., Shenoy M., Vaidyanathan P, Foreman J.W., Rasoulpour M., Thameem F, Al-Shahrouri H.Z., Radhakrishnan J., Gharavi A.G., Goilav B., Lifton R.P. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012, 482(7383):98-102.
69. Ji A.X., Privé G.G. Crystal structure of KLHL3 in complex with Cullin3. PLoS One 2013, 8(4):e60445.
70. Ohta A., Schumacher F.R., Mehellou Y., Johnson C., Knebel A., Macartney T.J., Wood N.T., Alessi D.R., Kurz T. The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. The Biochemical Journal 2013, 451(1):111-122.
71. Ruilope L.M., Bakris G.L. Renal function and target organ damage in hypertension. European Heart Journal 2011, 32(13):1599-1604.
72. Cirak S., von Deimling F, Sachdev S., Errington W.J., Herrmann R., Bönnemann C., Brockmann K., Hinderlich S., Lindner T.H., Steinbrecher A., Hoffmann K., Privé G.G., Hannink M., Nürnberg P., Voit T. Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. Brain 2010, 133(Pt 7):2123-2135.
73. Shibata S., Zhang J., Puthumana J., Stone K.L., Lifton R.P. Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(19):7838-7843.
74. Lin S.H., Yu I.S., Jiang S.T., Lin S.W., Chu P., Chen A., Sytwu H.K., Sohara E., Uchida S., Sasaki S., Yang S.S. Impaired phosphorylation of Na(+)-K(+)-2Cl(-) cotransporter by oxidative stress-responsive kinase-1 deficiency manifests hypotension and Bartter-like syndrome. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(42):17538-17543.
75. Edelmann M.J., Nicholson B., Kessler B.M. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Reviews in Molecular Medicine 2011, 13:e35.
76. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. Journal of the National Cancer Institute 2011, 103(13):1007-1017.
77. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov I.V., Oberoi P., Li C.C., Kenten J.H., Beutler J.A., Vousden K.H., Weissman A.M. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Research 2007, 67(19):9472-9481.
78. Soucy T.A., Smith P.G., Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clinical Cancer Research 2009, 15(12):3912-3916.
79. Nawrocki S.T., Kelly KR, Smith P.G., Espitia C.M., Possemato A., Beausoleil SA, Milhollen M., Blakemore S., Thomas M., Berger A., Carew J.S. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clinical Cancer Research 2013, ([Epub ahead of print]).
80. Luo Z., Yu G., Lee H.W., Li L., Wang L, Yang D, Pan Y., Ding C., Qian J., Wu L., Chu Y., Yi J, Wang X., Sun Y., Jeong L.S., Liu J., Jia L. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Research 2012, 72(13):3360-3371.
81. Zhao Y., Sun Y. Cullin-RING Ligases as attractive anti-cancer targets. Current Pharmaceutical Design 2013, 19(18):3215-3225.